The most potent weight-loss drug in development just moved a step closer. New trial results for retatrutide, a triple-hormone injectable, showed nearly 30% body-weight loss, approaching territory once reserved for surgery.
New Phase 3 results reported in May 2026 showed the investigational triple agonist retatrutide (Eli Lilly) producing nearly 30 percent average body-weight loss, about 70 pounds, over roughly 80 weeks at a higher dose, the strongest among GLP-1-class candidates. It targets three hormone receptors. Retatrutide is not FDA-approved and remains in development.
If GLP-1 medicines redefined weight loss, the next wave aims to push results further still.
May brought striking new data for the most potent candidate yet.
Eli Lilly reported new clinical results for retatrutide, an investigational injectable that targets three appetite-regulating receptors, GLP-1, GIP, and glucagon, more than the one or two targeted by current drugs. In the data summarized in May, a higher weekly dose over roughly 80 weeks helped participants lose close to 30 percent of body weight on average, about 70 pounds, the largest reduction reported among the GLP-1-class pipeline, with one expert noting it approaches results historically associated with bariatric surgery. Earlier Phase 3 (TRIUMPH) data had shown up to about 28.7 percent weight loss.
These results move retatrutide a step closer to a potential FDA submission, though it remains investigational. Triple-agonist potency also brings questions the agency and clinicians will weigh, including tolerability and the preservation of muscle versus fat during rapid loss. Timelines vary; some analysts anticipate potential approval no earlier than 2027 to 2028.
For consumers, retatrutide signals that even more effective options may be coming, but it is not available now, and bigger average weight loss is not automatically right for everyone. Potency raises its own considerations, side effects, nutrition, and muscle preservation during rapid loss, that require medical oversight. Trial averages describe studied groups, not individuals, and any future use would be a clinical decision with a prescriber.
Watch for an FDA submission and the full data on tolerability, safety, and body-composition effects, which will shape how retatrutide is positioned if approved. Comparisons with tirzepatide, CagriSema, and others will sharpen as data matures. For individuals, the practical posture is patience: in trials is not approved, timelines can shift, and decisions about any future drug belong with a clinician based on its specific evidence and your health profile.